Quantcast
Last updated on April 23, 2014 at 21:24 EDT

Latest Cytomegalovirus Stories

2010-09-15 08:30:00

BOSTON and RESEARCH TRIANGLE PARK, N.C., Sept. 15 /PRNewswire/ -- Chimerix, Inc., a pharmaceutical company developing orally-available antiviral therapeutics, today presented promising clinical data for CMX001 in a late-breaker poster session at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Wendy Painter, M.D., Chief Medical Officer of Chimerix, presented pharmacokinetic and preliminary safety data pertaining to renal function from 46 patients...

2010-09-13 12:44:31

A team of Welsh scientists have successfully cloned a human virus offering new hope for the treatment of potentially life-threatening diseases. Human cytomegalovirus (HCMV) is a major infectious cause of congenital malformations worldwide. The virus is also known to cause life-threatening disease in transplant patients and people with HIV/AIDS. The development of new treatments has been hampered as scientists have been unable to stably replicate HCMV outside the human body. Dr Richard Stanton...

2010-06-24 15:37:16

Cytomegalovirus (CMV) disease is a serious complication after allogeneic hematopoietic stem cell transplantation (allo-SCT), which is widely accepted as a curative therapy for advanced hematological malignancies including leukemia and malignant lymphoma. CMV disease can involve many organs and stomach is a common target. Few reports have been published regarding endoscopic examination in diagnosing CMV gastritis after allo-SCT. A research team from Japan demonstrated the endoscopic findings...

2010-06-02 07:30:00

RESEARCH TRIANGLE PARK, N.C., June 2 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch, President and Chief Executive Officer, will present at two upcoming investor conferences: the 9th Annual Needham Healthcare Conference, 9:00 AM ET, June 9, 2010, and the Jefferies 2010 Global Life Sciences Conference, 12:45 PM ET, June 11, 2010. The conferences are being held in New York City. Mr. Moch will...

2010-05-13 07:30:00

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable...

2010-05-06 07:30:00

RESEARCH TRIANGLE PARK, N.C., May 6 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Thomas A. Pitler, Ph.D., has joined the company as Vice President, Business Development. Dr. Pitler brings to Chimerix more than 25 years of experience, combining skills in business development and strategic planning with a strong scientific and financial background. Dr. Pitler has overall responsibility for the business...

2010-05-04 13:33:39

A national study involving a UT Southwestern Medical Center neonatologist and pediatric infectious diseases specialist suggests that a screening test routinely performed in newborns is not very good at identifying cytomegalovirus (CMV) infection, a leading cause of hearing loss in children. The findings, published in the April 14 issue of the Journal of the American Medical Association, suggest that testing blood drawn from a newborn's heel has limited value in detecting CMV infection. The...

2010-05-04 07:30:00

RESEARCH TRIANGLE PARK, N.C., May 4 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced today that Kenneth I. Moch has been appointed President and Chief Executive Officer. Mr. Moch joined Chimerix as Chief Operating Officer in July 2009, bringing more than 25 years of experience in creating, managing and financing biomedical companies. Mr. Moch will also join the company's Board, for a total of six directors. George...

d5265f0b60fe30a24d5122c06af9b8b6
2010-04-02 11:21:54

A study published in this week's online edition of Science has uncovered how the cytomegalovirus (CMV) is able to re-infect people in spite of the presence of a strong immune response. Research conducted at the Oregon Health & Science University (OHSU) Vaccine and Gene Therapy Institute (VGTI) showed that CMV re-infection can only take place when the virus invades a specific type of white blood cell--the CD8+ T cells--which attack and kill infected cells. "CMV is one of a few virus types...

2010-03-09 07:30:00

RESEARCH TRIANGLE PARK, N.C., March 9 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV). CMX001 is a broad-spectrum antiviral agent with demonstrated activity against double-stranded DNA (dsDNA) viruses. The Phase 2 randomized, double-blind,...


Latest Cytomegalovirus Reference Libraries

0_bbd337098cfaf28eafeb5f5f010e48ef
2011-01-12 15:30:34

Cytomegalovirus, a herpes viral genus, is known in humans as HCMV. It is part of the Betaherpesvirinae subfamily. Other herpesviruses fall into the subfamilies of Alphaherpesvirinae or Gammaherpesvirinae. xHCMV infections are frequently associated with salivary glands. It can be lethal for people who are immunocompromised. Other CMV viruses are found in several mammal species, but species isolated from animals differ from HCMV in terms of genomic structure. HCMV is found all over the...

More Articles (1 articles) »